Sorafenib VS TACE in HCC Patients With Portal Vein Invasion

Phase 2 Terminated 2 enrolled Seoul National University Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators are going to compare the therapeutic effect of sorafenib and transarterial chemoembolization in advanced hepatocellular carcinoma with major branch of portal vein invasion.

Timeline

Start: 2012-06
Primary completion: 2015-12
Completion: 2015-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Sorafenib	Small molecule	400 mg	Oral

Sorafenib VS TACE in HCC Patients With Portal Vein Invasion

Summary

Timeline

Drugs

Indications